Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Latest news / News 2016 / Prominent UK specialist to share biosimilar experience – health system savings and expanded patient access to the latest treatments

Prominent UK specialist to share biosimilar experience – health system savings and expanded patient access to the latest treatments

November 28, 2016 By Emilia

28 November 2016

Visiting UK clinician may have the solution to healthcare affordability, enabling wider patient access to the latest medicines while delivering savings to the Pharmaceutical Benefits Scheme (PBS) budget.

Dr Paul Cornes, an oncologist from Bristol is visiting Australia this week to encourage doctors and policy makers to embrace the patient and health system opportunities with biosimilars and to share international best practice as a key to advancing future care.

This is an excellent opportunity for Australia to hear from an international expert who uses biosimilars in his clinical practice and influences healthcare policy throughout Europe.

Speaking from personal experience, Dr Cornes will meet with a range of policy makers, clinicians, and consumer groups, providing examples of how government policy can enhance individual patient care. He has seen how greater uptake of biosimilars deliver affordable healthcare, the best patient outcomes and can fund future innovations in medicine.

As an example, he will outline how biosimilar filgrastim (used to treat neutropenia, or low white blood cell count, that threatens infections in people undergoing cancer chemotherapy) enables him to treat patients with lower risk or earlier stage disease, resulting in five times more patients being treated over two years, all while delivering millions in NHS savings that can be reinvested in new treatments.

Dr Cornes will encourage Australian doctors to take a leadership role in using biosimilars and not to let a perceived risk of immunogenicity prevent them from embracing the opportunity with biosimilars, outlining that in over ten years of clinical experience with biosimilars in Europe, enhanced immunogenicity has not been observed.

-ENDS-

BACKGROUND:

A biosimilar is a biological medicine that is determined to be comparable in quality, safety, and efficacy to the reference biological medicine following a full evaluation by the TGA. Biosimilars offer therapeutically equivalent and more cost-effective alternatives to existing, high-cost biological medicines.

Previously the Generic Medicines Industry Association (GMiA), the Generic and Biosimilar Medicines Association announced a name change in July 2015 to signal the significant role the association will continue to play in the access to affordable medicines.

The Generic and Biosimilar Medicines Association is the national association representing companies that manufacture, supply and export generic and biosimilar medicines. The generic and biosimilar medicines sector is a high value-add sector delivering significant health and economic benefits to the Australian public.

The availability of generic and biosimilar medicines in this country helps to deliver:

  • timely access to affordable medicines; substantial savings to the Pharmaceutical Benefit Scheme; and
  • thousands of highly skilled jobs; and domestic manufacturing and exports of over  $300

million

Generic and biosimilar medicines deliver the same health benefit to all Australians as the original brand and they must meet the same strict Australian standards, including the same manufacturing requirements, as branded medicines.

Filed Under: News 2016

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Announcement of Independent Chair

December 9, 2020

9 December 2020 Canberra, ACT Global health policy powerhouse, Jane Halton AO PSM, joins GBMA as its inaugural Independent … More...

Confidence in biosimilar medicines, amongst specialists, GP’s and Pharmacists

December 8, 2020

12 November 2020 Canberra, ACT New research shows prescriber … More...

IGBA Launches First Global Biosimilars Week

December 7, 2020

16 November 2020 Geneva, Switzerland Today the International Generic and … More…

© 2021 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us